Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Research & Development (2016 - 2025)

Lineage Cell Therapeutics' Research & Development history spans 16 years, with the latest figure at $8.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 140.67% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $17.7 million, up 42.15%, while the annual FY2025 figure was $17.7 million, 42.15% up from the prior year.
  • Research & Development reached $8.2 million in Q4 2025 per LCTX's latest filing, up from $3.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $24.8 million in Q4 2021 to a low of $2.8 million in Q3 2021.
  • Average Research & Development over 5 years is $4.7 million, with a median of $3.3 million recorded in 2021.
  • Peak YoY movement for Research & Development: surged 850.44% in 2021, then tumbled 83.44% in 2022.
  • A 5-year view of Research & Development shows it stood at $24.8 million in 2021, then crashed by 83.44% to $4.1 million in 2022, then fell by 4.82% to $3.9 million in 2023, then decreased by 12.37% to $3.4 million in 2024, then surged by 140.67% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Research & Development are $8.2 million (Q4 2025), $3.3 million (Q3 2025), and $3.1 million (Q2 2025).